SEC Form 4 · accession 0001140361-18-036639
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander Mark Schobel
Officer — Chief Innovation/Tech Officer
Period of report
Aug 15, 2018
Accepted (ET)
Aug 17, 2018 · 6:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001398733
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $16.46 | Aug 15, 2018 | A | 28,043 | A | — | Aug 15, 2028 | Common Stock | 28,043 | 28,043 | D |
| Restricted Stock UnitF2,F3 | — | Aug 15, 2018 | A | 2,636 | A | — | — | Common Stock | 2,636 | 2,636 | D |
Explanation of responses
- F1The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof.